BMS' Yervoy (ipilimumab) is now approved in Europe to be used in the treatment of advanced melanoma. The drug was approved in March for use in the US and is the first treatment to extend lives of patients with melanoma. BMS gained the drug when it acquired its partner Medarex and its pipeline.
Since, Yervoy's approval in March, BMS has worked a collaboration deal with Roche to test Yervoy as a combination therapy. BMS says it will look to do more of these type of deals in the future as combination therapies are expected to gain in popularity as a treatment strategy. See Fierce Biotech.
Posted by Bruce Lehr July 14th 2011.
Comments